• Items
  • Login
  • Register

How Does FDA’s Recent Guidance on Remote Interactive Evaluations Change the Inspections Landscape?

Add to Cart
Back to Results
Recorded May 26, 2021 | On-Demand Webinar

After great anticipation, in April 2021 FDA issued the guidance, “Remote Interactive Evaluations of Drug Manufacturing and Bioresearch Monitoring Facilities During the COVID-19 Public Health Emergency.” This guidance describes FDA’s process during the remainder of the COVID-19 public health emergency for conducting voluntary remote interactive evaluations at medical product manufacturing, processing, packing, or holding facilities; facilities covered under FDA’s bioresearch monitoring program; and outsourcing facilities. In May 2021, FDA also released its “Resiliency Roadmap for FDA Inspectional Oversight,” summarizing FDA’s inspectional activities during COVID-19 and the agency’s future inspection-related priorities. How will FDA determine whether a company is eligible for a remote interactive evaluation? How is a remote interactive evaluation different from an in-person inspection? What should facilities expect and how should they prepare? Speakers will address these issues and look to the future for how FDA could use virtual inspections beyond the pandemic to expedite reviews and approvals.

Assign Members : 
Members Assigned | Assign all contacts Unassign all contacts

  • All
  • Assigned
  • Unassigned
Add New Contact

Add New Contact





Cancel
Save

Assign Full Name Account Name Email Role
Total Records - Showing Page

Discounts and special pricing for additional items will be applied once you add the item to your cart.
Previous Next